KR20220092745A - A composition for stimulating growth of hairs contaning natural complex extracts - Google Patents
A composition for stimulating growth of hairs contaning natural complex extracts Download PDFInfo
- Publication number
- KR20220092745A KR20220092745A KR1020200183916A KR20200183916A KR20220092745A KR 20220092745 A KR20220092745 A KR 20220092745A KR 1020200183916 A KR1020200183916 A KR 1020200183916A KR 20200183916 A KR20200183916 A KR 20200183916A KR 20220092745 A KR20220092745 A KR 20220092745A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- hair
- comparative example
- pharmaceutical composition
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 210000004209 hair Anatomy 0.000 title claims description 52
- 230000012010 growth Effects 0.000 title description 7
- 230000004936 stimulating effect Effects 0.000 title 1
- 241000209140 Triticum Species 0.000 claims abstract description 27
- 235000021307 Triticum Nutrition 0.000 claims abstract description 27
- 230000003779 hair growth Effects 0.000 claims abstract description 27
- 230000001737 promoting effect Effects 0.000 claims abstract description 27
- 235000007238 Secale cereale Nutrition 0.000 claims abstract description 21
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 16
- 244000082988 Secale cereale Species 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 14
- 239000010018 saw palmetto extract Substances 0.000 claims description 14
- 244000179886 Moringa oleifera Species 0.000 claims description 13
- 235000011347 Moringa oleifera Nutrition 0.000 claims description 13
- 229940107605 borage extract Drugs 0.000 claims description 12
- 235000020704 flaxseed extract Nutrition 0.000 claims description 12
- 229940107657 flaxseed extract Drugs 0.000 claims description 12
- 235000020741 pine bark extract Nutrition 0.000 claims description 9
- 229940106587 pine bark extract Drugs 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 8
- 229940063845 saw palmetto extract Drugs 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 241000195940 Bryophyta Species 0.000 claims description 3
- 239000008266 hair spray Substances 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 28
- 240000004355 Borago officinalis Species 0.000 abstract description 5
- 235000007689 Borago officinalis Nutrition 0.000 abstract description 5
- 235000004426 flaxseed Nutrition 0.000 abstract description 5
- 240000006240 Linum usitatissimum Species 0.000 abstract description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000036559 skin health Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 97
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- -1 phytosterol Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 235000013376 functional food Nutrition 0.000 description 19
- 239000000796 flavoring agent Substances 0.000 description 18
- 235000013355 food flavoring agent Nutrition 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 15
- 241000209056 Secale Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000036541 health Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000013373 food additive Nutrition 0.000 description 8
- 239000002778 food additive Substances 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 6
- 241000018646 Pinus brutia Species 0.000 description 6
- 235000011613 Pinus brutia Nutrition 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000007760 free radical scavenging Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000010356 sorbitol Nutrition 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 240000006661 Serenoa repens Species 0.000 description 3
- 235000005318 Serenoa repens Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000000378 calcium silicate Substances 0.000 description 3
- 229910052918 calcium silicate Inorganic materials 0.000 description 3
- 235000012241 calcium silicate Nutrition 0.000 description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 235000010204 pine bark Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 229960003500 triclosan Drugs 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 240000005020 Acaciella glauca Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000005105 Pinus pinaster Nutrition 0.000 description 2
- 241001236212 Pinus pinaster Species 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000012812 general test Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 229940043810 zinc pyrithione Drugs 0.000 description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000974482 Aricia saepiolus Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 235000018782 Dacrydium cupressinum Nutrition 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001632576 Hyacinthus Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 235000008577 Pinus radiata Nutrition 0.000 description 1
- 241000218621 Pinus radiata Species 0.000 description 1
- 235000013697 Pinus resinosa Nutrition 0.000 description 1
- 235000008582 Pinus sylvestris Nutrition 0.000 description 1
- 235000008585 Pinus thunbergii Nutrition 0.000 description 1
- 241000218686 Pinus thunbergii Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- ZWXYEWJNBYQXLK-UHFFFAOYSA-N azanium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [NH4+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O ZWXYEWJNBYQXLK-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229940111793 eggplant extract Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003700 hair damage Effects 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 101150072261 large T gene Proteins 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001839 pinus sylvestris Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003135 vibrissae Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 모발의 손상 및 자극을 최소화함과 동시에 모발의 성장을 촉진할 수 있는 조성물에 관한 것이다.The present invention relates to a composition capable of promoting hair growth while minimizing hair damage and irritation.
동물들은 계절에 따라 털이 전체적으로 교체되는 털갈이 시기가 있으나, 인간은 전체 모발 중 일부가 매일 계속적으로 교체되어 항상 비슷한 개수가 유지된다.Animals have a molting period in which the entire hair is replaced according to the season, but in humans, a part of the total hair is continuously replaced every day, so that a similar number is always maintained.
모발의 주기(hair cycle)는 성장기, 퇴행기, 휴지기의 3주기로 나뉠 수 있으며, 그 중 성장기(anagen)는 모유두에서 활발한 세포 분열이 일어나 새로운 모발의 성장이 촉진되는 시기로, 이 시기에 모발이 성장할 수 있다.The hair cycle can be divided into three cycles: growth phase, regression phase, and resting phase. Among them, the anagen phase is a period in which active cell division occurs in the dermal papilla to promote the growth of new hair. can
모발의 상장 주기는 대략 남성은 3 내지 5년, 여성은 4 내지 6년 정도이며 전체적으로 약 80 내지85%의 모발이 성장기에 해당한다. The hair growth cycle is about 3 to 5 years for men and 4 to 6 years for women, and about 80 to 85% of hair is in the growth phase as a whole.
퇴행기(catagen)는 세포 분열이 점차 멈추어 가는 시기로 대략 3 내지 4주 정도이다. 마지막으로 휴지기(talogen)는 모유두가 위축되어 모발이 모세혈관과 분리되어 단순히 두피에 박혀 있는 시기로, 대략 3개월 정도이며 휴지기에 있는 모발은 대개 물리적 자극에 의해 쉽게 모피에서 이탈된다.Catagen is a period in which cell division gradually stops and lasts for about 3 to 4 weeks. Lastly, the talogen is a period in which the dermal papilla is atrophied and the hair is separated from the capillaries and simply embedded in the scalp, for about 3 months.
인간의 모발은 비록 생명과는 무관하나, 사람의 인상 및 외모에 결정적인 영향을 미치기 때문에 사회적으로 많은 관심이 집중되고, 종래 탈모가 증상으로 인식되었던 것과 달리 최근에는 질환이라는 인식이 증대되고 있다.Although human hair has nothing to do with life, it has a decisive effect on the impression and appearance of a person, so socially much attention is focused on it, and unlike the conventional hair loss that has been recognized as a symptom, the recognition as a disease is increasing in recent years.
특히, 최근 고도화, 산업화가 가속되면서 수반되는 과도한 스트레스, 생활 습관의 사회 문화적인 요인들로 인해 탈모 인구가 급격히 증가하고 있다.In particular, with the recent acceleration of advancement and industrialization, the number of people with hair loss is rapidly increasing due to excessive stress and socio-cultural factors of lifestyle.
또한, 최근에는 중년 남성뿐 아니라 장년층의 탈모가 증가하고 있어 탈모의 다양한 원인을 분석하고 이를 해결하기 위한 연구가 활발히 진행되고 있다.In addition, in recent years, hair loss not only in middle-aged men but also in middle-aged people is increasing. Therefore, various causes of hair loss are analyzed and research is being actively conducted to solve them.
한편, 화장품 업계에서는 여러 화학물질 등에 의한 피부 자극을 줄이기 위해 천연물을 사용한 제품이 다수 개발되고 있다. 천연 재료는 피부에 부작용이 적을 뿐 아니라, 최근 천연 재료를 이용한 화장품에 대한 소비자들의 호응이 높아짐에 따라 화장품 원료로서 개발가치가 한층 늘어나고 있다.On the other hand, in the cosmetic industry, a number of products using natural products have been developed to reduce skin irritation caused by various chemicals. Natural ingredients have fewer side effects on the skin, and as consumers' response to cosmetics using natural ingredients increases, the value of development as a cosmetic raw material is increasing.
따라서, 소비자의 호응도가 높은 천연 재료를 이용한 화장품의 수요가 점차 증가하고 있으며, 생체 안전성 및 피부 개선 효과가 우수한 다기능성(multi-funtional) 화장품 개발에 대한 다양한 연구가 활발하게 이루어지고 있다.Therefore, the demand for cosmetics using natural ingredients with high consumer response is gradually increasing, and various studies on the development of multi-functional cosmetics with excellent biosafety and skin improvement effects are being actively conducted.
본 발명은 전술한 종래 기술의 문제점을 해결하기 위한 것으로, 본 발명의 목적은 천연 원료를 유효성분으로 포함하여 피부 건강에 유익할 뿐만 아니라, 탈모 방지 및 육모 촉진능이 우수한 조성물을 제공하는 것이다.The present invention is to solve the problems of the prior art described above, and an object of the present invention is to provide a composition containing natural raw materials as an active ingredient, which is beneficial to skin health as well as excellent in preventing hair loss and promoting hair growth.
본 발명의 일 측면에 따르면, 호밀 추출밀, 아마씨 추출물, 밀배아 추출물, 및 보리지 추출물을 유효성분으로 포함하는 탈모 방지 및 발모 촉진용 약학 조성물이 제공된다.According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing hair loss and promoting hair growth comprising rye extract, flaxseed extract, wheat germ extract, and borage extract as active ingredients.
일 실시예에 있어서, 상기 약학 조성물이 소나무 껍질 추출물 또는 톱야자 추출물을 더 포함할 수 있다.In one embodiment, the pharmaceutical composition may further comprise a pine bark extract or saw palmetto extract.
일 실시예에 있어서, 상기 약학 조성물이 모링가 추출물을 더 포함할 수 있다.In one embodiment, the pharmaceutical composition may further include a Moringa extract.
일 실시예에 있어서, 상기 약학 조성물이 비오틴을 더 포함할 수 있다.In one embodiment, the pharmaceutical composition may further include biotin.
일 실시예에 있어서, 상기 약학 조성물이 항염, 항균 활성 및 세포 증식능을 더 포함할 수 있다.In one embodiment, the pharmaceutical composition may further include anti-inflammatory, antibacterial activity and cell proliferation.
본 발명의 다른 측면에 따르면, 호밀 추출밀, 아마씨 추출물, 밀배아 추출물, 및 보리지 추출물을 유효성분으로 포함하는 탈모 방지 및 발모 촉진용 식품 조성물이 제공된다.According to another aspect of the present invention, there is provided a food composition for preventing hair loss and promoting hair growth comprising rye extract, flaxseed extract, wheat germ extract, and borage extract as active ingredients.
일 실시예에 있어서, 상기 식품 조성물이 소나무 껍질 추출물 또는 톱야자 추출물을 더 포함할 수 있다.In one embodiment, the food composition may further include a pine bark extract or saw palmetto extract.
본 발명의 다른 측면에 따르면, 호밀 추출밀, 아마씨 추출물, 밀배아 추출물, 및 보리지 추출물을 유효성분으로 포함하는 탈모 방지 및 발모 촉진용 화장료 조성물이 제공된다.According to another aspect of the present invention, there is provided a cosmetic composition for preventing hair loss and promoting hair growth comprising rye extract wheat, flaxseed extract, wheat germ extract, and borage extract as active ingredients.
일 실시예에 있어서, 상기 화장료 조성물이 헤어토너, 헤어로션, 헤어크림, 헤어스프레이, 헤어무스, 헤어젤, 헤어비누, 헤어샴푸, 헤어린스, 헤어팩, 및 헤어트리트먼트로로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있다.In one embodiment, the cosmetic composition is one selected from the group consisting of hair toner, hair lotion, hair cream, hair spray, hair mousse, hair gel, hair soap, hair shampoo, hair conditioner, hair pack, and hair treatment. It can be formulated as above.
발명의 일 측면에 따른 조성물은 천연 복합 추출물에 포함된 유효성분들이 상호 작용하여 사용자의 피부 건강에 유익하면서도 탈모 방지 및 발모 촉진 효과가 극대화될 수 있다. In the composition according to one aspect of the invention, the active ingredients contained in the natural complex extract interact to maximize the effect of preventing hair loss and promoting hair growth while being beneficial to the user's skin health.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.It should be understood that the effects of the present invention are not limited to the above-described effects, and include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.The terms used in this specification have been selected as currently widely used general terms as possible while considering the functions in the present invention, but these may vary depending on the intention or precedent of a person skilled in the art, the emergence of new technology, and the like. In addition, in a specific case, there is a term arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the corresponding invention. Therefore, the term used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than the name of a simple term.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다. Unless defined otherwise, all terms used herein, including technical and scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms such as those defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related art, and should not be interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application. does not
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.Numerical ranges are inclusive of the values defined in that range. Every maximum numerical limitation given throughout this specification includes all lower numerical limitations as if the lower numerical limitation were expressly written. Every minimum numerical limitation given throughout this specification includes all higher numerical limitations as if the higher numerical limitation were expressly written. Any numerical limitation given throughout this specification shall include all numerical ranges within the broader numerical range, as if the narrower numerical limitation were expressly written down.
이하, 본 발명의 실시예를 상세히 기술하나, 하기 실시예에 의해 본 발명이 한정되지 아니함은 자명하다.Hereinafter, examples of the present invention will be described in detail, but it is obvious that the present invention is not limited by the following examples.
본 발명의 일 측면에 따르면, 호밀 추출밀, 아마씨 추출물, 밀배아 추출물, 및 보리지 추출물을 유효성분으로 포함하는 탈모 방지 및 발모 촉진용 약학 조성물이 제공된다.According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing hair loss and promoting hair growth comprising rye extract, flaxseed extract, wheat germ extract, and borage extract as active ingredients.
상기 약학 조성물은 천연 유래의 복합 추출물을 유효성분으로 포함하여 탈모 방지 및 육모 촉진 활성뿐만 아니라 생체 안전성이 우수하다. The pharmaceutical composition is excellent in biosafety as well as hair loss prevention and hair growth promoting activity by including a natural-derived complex extract as an active ingredient.
특히, 상기 복합 추출물은 인체 내에서 복합적으로 작용하므로, 단일 추출물과 비교하여 탈모 방지 및 발모 촉진 효과가 현저히 우수하다.In particular, since the complex extract acts in a complex way in the human body, the effect of preventing hair loss and promoting hair growth is remarkably superior compared to a single extract.
또한, 상기 약학 조성물은 모발 성장을 효과적으로 촉진할 뿐만 아니라, 항염, 항균 활성 및 세포 증식능이 뛰어나 비듬 방지 효과 및 두피 염증 완화 효과가 우수하다.In addition, the pharmaceutical composition not only effectively promotes hair growth, but also has excellent anti-inflammatory, antibacterial, and cell proliferation ability, and thus has excellent anti-dandruff and scalp inflammation alleviation effects.
상기 “호밀(Secale cereale)”은 라이보리라고도 하며, 캅카스, 터키 원산이다. 상기 호밀 잎은 녹청색으로 어린 잎의 윗면에는 벨벳 모양의 털이 밀생한다. 상기 호밀은 식이섬유를 다량 함유하므로 섭취자에게 포만감도 주고 열량이 낮아 다이어트에 효과적이다. 상기 호밀은 탄수화물뿐만 아니라, 그 외에 단백질, 칼륨, 비타민 B도 함유하고 있어 소화를 용이하게 하며 변비를 예방하는 효과를 나타낸다The "rye ( Secale cereale )" is also called ribori, and is native to the Caucasus and Turkey. The rye leaves are greenish-blue, and velvet-shaped hairs are densely grown on the upper surface of the young leaves. Since the rye contains a large amount of dietary fiber, it gives a feeling of satiety to the consumer and is effective for dieting due to low calorie. The rye not only contains carbohydrates, but also contains protein, potassium, and B vitamins, thereby facilitating digestion and preventing constipation.
상기 호밀 추출물(Rye extract)은 호밀의 씨(seed)나 겨를 추출하여 수득할 수 있으나, 그 부위가 특별히 제한되는 것은 아니다.The rye extract (Rye extract) may be obtained by extracting the seeds or bran of rye, but the portion is not particularly limited.
상기 “아마(Linum usitatissimum)“는 중앙아시아 고상지대가 원산지인 아마과(Linaceae) 식물로서 파종 후 100일이면 수확이 가능한 단기식물로 북위 55도의 한랭한 지역에서 자란다.The "flax ( Linum usitatissimum )" is a plant of the Linaceae family, which is native to the highlands of Central Asia.
상기 아마씨는 1년생 견과류 식물의 종자로서, 줄기는 70 내지 100cm인데 반해 뿌리는 3m에 이르며, 다량의 유기물질을 필요로 하는 생장조건 때문에 한번 재배하면 7년간은 연작이 되지 않는 특성으로 오메가-3, 식이섬유, 리그닌 토코페롤, 엽산, 미네랄 등 수많은 필수 성분이 집약되어 있다.The flaxseed is a seed of a one-year-old nut plant, the stem is 70 to 100 cm, while the root reaches 3 m, and because of the growth conditions that require a large amount of organic material, once cultivated, it is not continuously cultivated for 7 years. , dietary fiber, lignin tocopherol, folic acid, minerals, etc. are concentrated.
상기 아마씨의 효능으로는 각종 혈관 및 심장질환예방, 뇌졸중의 예방 및 치료, 항암효과, 아토피성 피부염 등의 피부질환 및 두뇌의 성장 발육촉진 등이 있고, 상기 아마씨 추출물은 오메가-3 지방산, 오메가-6 지방산, 오메가-9 지방산 및 포화지방산을 다량 함유하는 아마씨 오일일 수 있다.The efficacy of the flaxseed includes prevention of various vascular and heart diseases, prevention and treatment of stroke, anticancer effect, skin diseases such as atopic dermatitis and promotion of brain growth and development, and the flaxseed extract contains omega-3 fatty acids, omega- It may be flaxseed oil, which contains high amounts of 6 fatty acids, omega-9 fatty acids and saturated fatty acids.
상기 “밀배아(wheat germ)”는 통밀을 밀가루로 처리하는 공정에서 제거되어 나오는 말알(wheat kernel)의 영양분이 풍부한 배아로서, 전체 밀알의 약 2 내지 3%를 차지한다. The “wheat germ” is a nutrient-rich embryo of a wheat kernel that is removed in a process of processing whole wheat into flour, and accounts for about 2-3% of the total wheat kernel.
상기 밀(Triticum vulgare)의 씨눈인 밀배아는 현재까지 항산화 비타민으로 알려진 비타민 E(토코페롤)가 풍부한 것으로 알려져 있고, 최근 연구에 따르면 밀배아에서 추출한 천연물질이 인체의 손상된 면역기능을 복원하는 효과가 있는 것으로 알려져 있다.Wheat germ, the seed of the wheat ( Triticum vulgare ), is known to be rich in vitamin E (tocopherol), known as an antioxidant vitamin so far, and according to a recent study, a natural substance extracted from wheat germ has the effect of restoring the human body's damaged immune function. It is known that there is
상기 밀배아 추출물은 밀의 배아를 압착하거나 추출하여 수득한 통상의 밀배아 오일일 수 있다.The wheat germ extract may be a conventional wheat germ oil obtained by pressing or extracting wheat germ.
상기 “보리지(Borrago officinalis)”는 보리지는 시리아가 원산지이며 현재 북아프리카, 중동, 유럽, 남아메리카, 지중해 지역에서 널리 재배된다.The "Borridge ( Borrago officinalis )" is a borage native to Syria and is currently widely cultivated in North Africa, the Middle East, Europe, South America, and the Mediterranean region.
상기 보리지는 전통의학에서 기침과 목감기 등에 염증과 통증을 완화하는 용도로, 일상생활에서 요리의 용도로 1500여 년 이상 쓰이고 있다. 현재 유럽에서는 주로 치유의 목적으로 보리지를 경작하고 샐러드, 수프 등의 요리에 사용하거나 건강보조식품으로 이용한다. 상기 보리지는 항염 활성, 피부 보습, 재생 효과가 뛰어나고 월경 전 증후군, 갱년기 증상 완화에 도움을 주는 것으로 알려져 있다.The borage is used in traditional medicine to relieve inflammation and pain, such as cough and sore throat, and has been used for more than 1500 years for cooking in everyday life. Currently, in Europe, barley is cultivated mainly for the purpose of healing and used in salads, soups, etc., or as a health supplement. The borage is known to have excellent anti-inflammatory activity, skin moisturizing, and regeneration effects, and to help relieve premenstrual syndrome and menopausal symptoms.
상기 보리지 추출물은 보리지의 다양한 부위를 추출하여 수득할 수 있으나, 구체적으로 보리지의 종자를 압착하여 추출한 통상의 식물성 오일일 수 있다. The borage extract may be obtained by extracting various parts of barley, but specifically may be a conventional vegetable oil extracted by squeezing the seeds of barley.
상기 “추출물”은 용매와 추출재료를 특정 조건하에서 접촉시킴으로써 추출 재료에 함유된 유효성분을 분리해낸 것을 의미한다.The "extract" means that the active ingredient contained in the extraction material is separated by contacting the solvent and the extraction material under specific conditions.
상기 복합 추출물은 정제수, 탄소수 1 내지 4개의 저급 알코올, 아세톤, 에틸아세테이트, 부틸아세테이트, 및 1,3-부틸렌글라이콜로 이루어진 군으로부터 선택되는 하나 이상의 용매로 추출될 수 있고, 상기 알코올은 60 내지 90% 농도(v/v)의 에탄올일 수 있다.The complex extract may be extracted with one or more solvents selected from the group consisting of purified water, lower alcohols having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, and 1,3-butylene glycol, and the alcohol is 60 to It may be ethanol at a concentration of 90% (v/v).
상기 원료에 포함된 유효성분은 용매의 극성에 따라 추출 비율이 상이해질 수 있으며, 상기 에탄올은 천연 원료의 생리 활성 물질 추출에 있어 선택성이 뛰어나므로 상기 에탄올 추출에 의해 최적의 발모 촉진 효과가 구현될 수 있다.The extraction ratio of the active ingredients contained in the raw material may be different depending on the polarity of the solvent, and since the ethanol has excellent selectivity in extracting the physiologically active substances of natural raw materials, the optimal hair growth promoting effect may be realized by the ethanol extraction. can
특히, 물과 에탄올은 극성이 상이하여, 각 극성에 따라 추출되는 유효성분이 달라질 수 있으며 최적의 발모 촉진 효과가 구현될 수 있도록 상기 에탄올의 농도를 적절히 제어할 수 있다. In particular, since water and ethanol have different polarities, the active ingredients extracted according to each polarity may vary, and the concentration of ethanol may be appropriately controlled so that an optimal hair growth promoting effect may be realized.
상기 에탄올은 농도가 90%(w/w) 초과이면 적정한 수율이 구현되지 않을 수 있고, 농도가 60%(w/w) 미만이면 발모를 촉진하는 유효성분이 충분하게 추출되지 않을 수 있다.If the concentration of the ethanol is more than 90% (w/w), an appropriate yield may not be realized, and if the concentration is less than 60% (w/w), the active ingredient that promotes hair growth may not be sufficiently extracted.
상기 복합 추출물은 각 원료를 물로 수세한 후 건조 및 분쇄하여, 원료 중량의 8 내지 12배에 달하는 부피의 용매로 약 1시간 내지 24시간 동안 환류 순환 추출, 가압 추출, 초음파 추출 등 통상적인 방법으로 추출 및 여과하여 제조할 수 있다. 또한, 상기 추출물은 감압 증류 또는 동결 건조 등과 같은 추가적인 공정에 의해 분말 상태로 수득할 수 있다.The complex extract is obtained by washing each raw material with water, then drying and pulverizing it, and using a solvent with a volume equivalent to 8 to 12 times the weight of the raw material, reflux circulation extraction, pressure extraction, ultrasonic extraction, etc. for about 1 hour to 24 hours. It can be prepared by extraction and filtration. In addition, the extract may be obtained in a powder state by an additional process such as distillation under reduced pressure or freeze-drying.
상기 추출물은 통상적인 정제 과정을 거친 추출물도 포함할 수 있다. 예컨대, 상기 추출물은 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획물을 포함할 수 있다.The extract may also include an extract that has undergone a conventional purification process. For example, the extract is separated using an ultrafiltration membrane having a constant molecular weight cut-off value, and various purification methods are additionally performed, such as separation by various chromatography (prepared for separation according to size, charge, hydrophobicity or affinity). It may include a fraction obtained through
한편, 상기 약학 조성물이 소나무 껍질 추출물 또는 톱야자 추출물을 더 포함할 수 있다.On the other hand, the pharmaceutical composition may further include a pine bark extract or saw palmetto extract.
상기 “소나무(pine tree)”는 적송(Pinus Densiflora), 해송(Pinus maritima 또는 Pinus pinaster), 뉴송(Pinus radiata), 곰솔(Pinus thunbergii), 구주소나무(Pinus sylvestris) 등 다양한 종류의 소나무를 모두 포함하는 의미로 사용될 수 있다.The "pine tree" is red pine ( Pinus Densiflora ), sea pine ( Pinus maritima or Pinus pinaster ), new pine ( Pinus radiata ), gom pine ( Pinus thunbergii ), pine tree ( Pinus sylvestris ), including all of various types of pine trees. can be used to mean
상기 소나무껍질은 속껍질과 겉껍질로 구분할 수 있는데, 양자를 모두 사용할 수 있다.The pine bark can be divided into an inner bark and an outer bark, and both can be used.
상기 소나무 껍질은 소나무 껍질은 다량의 천연 폴리페놀 성분을 함유하고 있으며, 프랑스해송껍질추출물에 대한 연구에 의하면, 소나무 껍질 추출물은 콜라겐 분해억제효과(Grimm et al., Free Rad Biol Med 36: 811-822, 2004), 기미제거효과(Ni et al., Phytother Res 16: 567-571, 2002), 피부탄력증진효과(D. Segger and F. Schonlau, J. Dermatol. Treatment, 15: 1-5, 2004), 부종개선효과(Arcangeli, Fitoterapia 71: 236-244, 2000), 생리통 완화 효과(Kohama & Suzuki, Eur Bull Drug Res, 7: 30-32, 1999), 혈관확장효과(D.F. Fitzpatrick et al., J. Cardiovasc. Pharm. 32: 509-515, 1998) 등 다양한 생리활성을 가진 것으로 알려져 있다.The pine bark contains a large amount of natural polyphenol components, and according to a study on the French sea pine bark extract, the pine bark extract has an inhibitory effect on collagen degradation (Grimm et al., Free Rad Biol Med 36: 811- 822, 2004), blemish removal effect (Ni et al., Phytother Res 16: 567-571, 2002), skin elasticity enhancing effect (D. Segger and F. Schonlau, J. Dermatol. Treatment, 15: 1-5, 2004), edema improvement effect (Arcangeli, Fitoterapia 71: 236-244, 2000), menstrual pain relief effect (Kohama & Suzuki, Eur Bull Drug Res, 7: 30-32, 1999), vasodilatory effect (D.F. Fitzpatrick et al. , J. Cardiovasc. Pharm. 32: 509-515, 1998) are known to have various physiological activities.
상기 “톱야자(Serenoa repens)”는 북미 아트란틱 해안을 따라 분포하며, 군락을 이루어 자라는 것이 보통인 진한 검붉은 열매를 가진 작은 야자수이다. 상기 톱야자 열매는 북미 인디안들이 전통적으로 비뇨-생식기 질환 등의 예방 및 치료의 목적으로 사용해 왔던 천연물로 최근 여러 연구를 통해 그 효능이 밝혀지고 있다.The " Serenoa repens " is a small palm tree with dark red fruits that is distributed along the Atlantic coast of North America, and usually grows in colonies. The saw palmetto fruit is a natural product that North American Indians have traditionally used for the purpose of preventing and treating urinary-genital diseases, etc., and its efficacy has been revealed through several recent studies.
상기 톱야자 열매의 유효성분은 사포닌, 지방산, 피토스테롤, 정유, 레신, 탄닌 등으로 알려져 있으며, 그 열매를 섭취하거나, 적절한 형태로 가공하여 사용하고 있다. 상기 톱야자는 일반적으로 추출을 통해 표준화된 원료로 가공하여 의약품 또는 건강기능식품으로 사용되고 있다.The active ingredients of the saw palmetto fruit are known as saponin, fatty acid, phytosterol, essential oil, lesin, tannin, and the like, and the fruit is ingested or processed into an appropriate form and used. The saw palmetto is generally processed into standardized raw materials through extraction and used as pharmaceuticals or health functional foods.
상기 톱야자 추출물은 상기 톱야자 나무의 다양한 부위를 추출하여 수득할 수 있으나, 바람직하게는 톱야자 열매의 유효성분을 추출하여 수득할 수 있다.The saw palmetto extract may be obtained by extracting various parts of the saw palmetto tree, but preferably it can be obtained by extracting the active ingredient of the saw palmetto fruit.
한편, 상기 약학 조성물이 모링가 추출물 및 비오틴을 더 포함할 수 있다.On the other hand, the pharmaceutical composition may further include a Moringa extract and biotin.
상기 “모링가(Moringa oleifera)”는 열대 및 아열대 기후에 널리 분포하는 십자화목과의 속씨식물 속의 하나이다. 상기 모링가는 우산과 같이 펼쳐진 4 내지 8 미터 높이의 관목이며, 30 내지 70cm 길이의 잎들은 낙엽성이며, 꽃들은 흰색이고 향기가 진하며, 열매는 혁질성 및 현수성의 긴 삼각형상의 긴 깍지로 길이는 30 내지 40cm 이다. 씨는 만곡 삼각형으로, 길이는 1.2 cm이고 폭은 1 cm이며, 길이 2cm인 3개의 막성 날개가 씨로부터 연장되어 있다.The "Moringa ( Moringa oleifera )" is one of the angiosperms of the Cruciferae family widely distributed in tropical and subtropical climates. The Moringa is an umbrella-like shrub with a height of 4 to 8 meters, leaves of 30 to 70 cm in length are deciduous, the flowers are white and fragrant, and the fruit is a long triangular long pod of hyacinth and suspension. 30 to 40 cm. Seed curved triangular, 1.2 cm long and 1 cm wide, with three membranous wings 2 cm long extending from the seed.
상기 모링가 나무는 극한 조건에도 생존하는 매우 신속 성장의 깊은 뿌리로 인하여 수개월동안 물 없는 상태에도 생존할 수 있다.The Moringa tree can survive without water for several months due to its very fast growing deep roots that survive extreme conditions.
상기 모링가 추출물은 모링가의 전초 또는 다양한 기관(예컨대, 잎, 꽃, 줄기, 뿌리 및 열매(씨) 등)로부터 수득할 수 있으며, 바람직하게는 모링가의 전초 또는 열매(씨), 가장 바람직하게는 전초를 추출하여 수득할 수 있다.The Moringa extract can be obtained from the outpost or various organs of Moringa (eg, leaves, flowers, stems, roots and fruits (seeds), etc.), preferably Moringa outposts or fruits (seeds), most preferably It can be obtained by extracting the forage.
상기 “비오틴(biotin)”은 내장, 알, 및 특정 채소와 같은 많은 식품에서 자연적으로 발견되는, 황(sulfur)을 함유하고 있는 비타민으로 지방과 탄수화물 대사에 관여한다.The "biotin" is a vitamin containing sulfur, found naturally in many foods, such as intestines, eggs, and certain vegetables, and is involved in fat and carbohydrate metabolism.
상기 비오틴은 피부와 두발에 좋은 영향을 미치기 때문에 '비타민 H'로 지칭되며, 혈구의 생성과 남성 호르몬 분비에 관여할 뿐만 아니라, 다른 비타민 B군과 함께 신경계와 골수의 기능을 원활하게 하는 것으로 알려져 있다.The biotin is referred to as 'vitamin H' because it has a good effect on the skin and hair, and is known not only to be involved in the production of blood cells and male hormone secretion, but also to facilitate the functions of the nervous system and bone marrow together with other B vitamins. have.
상기 약학 조성물은 상기 유효성분 이외에 약학적으로 허용되는 담체를 포함할 수 있다.The pharmaceutical composition may include a pharmaceutically acceptable carrier in addition to the active ingredient.
상기 약학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세 결정성셀룰로스, 폴리비닐피로리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일등을 포함하나, 이에 한정되는 것은 아니다. The pharmaceutically acceptable carriers are those commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.
또한, 상기 약학 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.In addition, the pharmaceutical composition may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
상기 약학 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환자의 상태 및 체중, 질병의 정도, 약물 형태, 투여 경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The pharmaceutical composition may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method, and the dosage may vary depending on the condition and weight of the patient, the degree of disease, the drug Although it varies depending on the form, administration route and time, it may be appropriately selected by those skilled in the art.
상기 약학 조성물은 약학적으로 유효한 양으로 투여할 수 있다. 상기 “약학적으로 유효한 양”은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The pharmaceutical composition may be administered in a pharmaceutically effective amount. The “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is dependent on the patient's type, severity, drug activity, and drug Sensitivity, administration time, administration route and excretion rate, duration of treatment, factors including concomitant drugs, and other factors well known in the medical field.
상기 약학 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래 의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. The pharmaceutical composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple.
상기한 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.
구체적으로 상기 약학 조성물의 유효량은 환자의 연령, 성별, 상태, 체중, 체내에 활성 성분의 흡수도, 불활성율 및 배설 속도, 질병 종류, 병용되는 약물에 따라 달라질 수 있으며, 일반적으로는 체중 1kg 당 0.001 내지 150mg, 바람직하게는 0.01내지 100mg을 매일 또는 격일 투여하거나, 1일 1 내지 3회로 나누어 투여할 수 있다.Specifically, the effective amount of the pharmaceutical composition may vary depending on the patient's age, sex, condition, weight, absorption of the active ingredient into the body, inactivation rate and excretion rate, disease type, and drugs used in combination, and generally per 1 kg of body weight. 0.001 to 150 mg, preferably 0.01 to 100 mg, may be administered daily or every other day, or divided into 1 to 3 times a day.
그러나 투여 경로, 비만의 중증도, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.However, since it may increase or decrease depending on the route of administration, the severity of obesity, sex, weight, age, etc., the dosage is not intended to limit the scope of the present invention in any way.
본 발명의 다른 측면에 따르면, 호밀 추출밀, 아마씨 추출물, 밀배아 추출물, 및 보리지 추출물을 유효성분으로 포함하는 탈모 방지 및 발모 촉진용 식품 조성물이 제공된다.According to another aspect of the present invention, there is provided a food composition for preventing hair loss and promoting hair growth comprising rye extract, flaxseed extract, wheat germ extract, and borage extract as active ingredients.
상기 “식품 조성물”은 통상적인 기능성 식품 또는 건강기능식품을 모두 포함하는 개념으로 이용될 수 있다.The "food composition" can be used as a concept including all of the conventional functional food or health functional food.
상기 기능성 식품은 통상의 식품 첨가물을 포함할 수 있으며, 상기 식품 첨가물은 다른 규정이 없는 한 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 적합성 여부를 판단할 수 있다.The functional food may include normal food additives, and unless otherwise specified, the food additives are approved by the Ministry of Food and Drug Safety according to the standards and standards for the relevant items in accordance with the general rules and general test methods of the Food Additives Code. suitability can be judged.
상기 식품 첨가물 공전에 기재된 품목은 예컨대 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류를 들 수 있다.Items described in the Food Additives Codex include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; Mixtures, such as an added alkali agent, a preservative agent, and a tar dye agent, are mentioned.
상기 기능성 식품은 항산화, 탈모, 염증질환 등의 개선을 위한 식품 및 음료 등에 다양하게 이용될 수 있으며, 예컨대, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강기능성 보조 식품, 식품 첨가제 등에 사용될 수 있다.The functional food can be variously used in foods and beverages for the improvement of antioxidants, hair loss, inflammatory diseases, etc. For example, it can be used in various foods, beverages, gum, tea, vitamin complexes, health functional supplements, food additives, etc. have.
상기 기능성 식품은 항산화, 탈모, 염증질환 등의 개선을 목적으로 정제, 과립, 분말, 캅셀, 액상의 용액 및 환으로 이루어진 군에서 선택된 어느 하나의 제형으로 제조 및 가공될 수 있다.The functional food may be manufactured and processed into any one formulation selected from the group consisting of tablets, granules, powders, capsules, liquid solutions, and pills for the purpose of improving antioxidant, hair loss, inflammatory diseases, and the like.
구체적으로 상기 정제 형태의 기능성 식품은 식물 추출물 또는 이의 분획물, 부형제, 결합제, 붕해제 및 다른 첨가제와의 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축 성형하거나, 상기 혼합물을 직접 압축 성형하여 제조할 수 있다. 또한, 상기 정제 형태의 기능성 식품은 필요에 따라 교미제 등을 함유할 수 있으며, 필요에 따라 적당한 제피제로 제피할 수도 있다.Specifically, the functional food in the form of a tablet is granulated by a conventional method by granulating a mixture with a plant extract or a fraction thereof, an excipient, a binder, a disintegrant, and other additives, and then compression molding by putting a lubricant, or the like, or directly applying the mixture It can be manufactured by compression molding. In addition, the functional food in the tablet form may contain a mating agent, etc., if necessary, and may be coated with a suitable skinning agent if necessary.
상기 캅셀 형태의 기능성 식품 중 경질캅셀제는 통상의 경질캅셀에 가지 추출물 및 부형제 등의 첨가제와의 혼합물 또는 그의 입상물 또는 제피한 입상물을 충진하여 제조할 수 있으며, 연질캅셀제는 식물 추출물 또는 이의 분획물, 및 부형제 등의 첨가제와의 혼합물을 젤라틴 등 캅셀기제에 충진하여 제조할 수 있다. 상기 연질캅셀제는 필요에 따라 글리세린 또는 솔비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Among the functional foods in the form of capsules, hard capsules can be prepared by filling conventional hard capsules with a mixture of eggplant extract and additives such as excipients, or their granules or skinned granules, and soft capsules are plant extracts or fractions thereof. , and it can be prepared by filling a mixture with additives such as excipients in a capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.
상기 환 형태의 기능성 식품은 식물 추출물 또는 이의 분획물, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 적당한 제피제로 제피를, 또는 전분, 탈크 또는 적당한 물질로 환의를 입힐 수도 있다.The functional food in the form of a ring can be prepared by molding a mixture of plant extracts or fractions thereof, excipients, binders, disintegrants, etc. by an appropriate method, and, if necessary, coating the skin with sucrose or other suitable skinning agent, or starch, talc or You can also dress the gown with a suitable material.
상기 과립형태의 기능성 식품은 식물 추출물 또는 이의 분획물, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다The functional food in the form of granules may be prepared in a granular form by an appropriate method by preparing a mixture of plant extracts or fractions thereof, excipients, binders, disintegrants, etc., and may contain flavoring agents, corrosive agents, etc.
또한, 상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함할 수 있다.In addition, the definitions of terms for the excipients, binders, disintegrants, lubricants, flavoring agents, and the like are described in documents known in the art and may include those having the same or similar functions.
상기 건강기능식품은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 말한다. The health functional food refers to a food manufactured and processed using raw materials or ingredients useful for the human body according to the Health Functional Food Act No. 6727, and controls nutrients or physiological action for the structure and function of the human body. It refers to ingestion for the purpose of obtaining useful effects for health purposes such as
상기 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정할 수 있다.The health functional food may contain normal food additives, and unless otherwise specified, whether it is suitable as a food additive is a standard for the item according to the general rules and general test methods of food additives approved by the Ministry of Food and Drug Safety. And it can be determined by the standard.
상기 건강기능식품은 담체, 희석제, 부형제 및 첨가제 중 하나 이상을 포함하여 정제, 환제, 산제, 과립제, 분말제, 켑슐제 및 액제 제형으로 이루어진 군에서 선택된 하나로 제형된 것을 특징으로 한다.The health functional food is characterized in that it is formulated with one selected from the group consisting of tablets, pills, powders, granules, powders, capsules and liquid formulations, including one or more of carriers, diluents, excipients and additives.
상기 건강기능식품에 첨가할 수 있는 식품으로는, 각종 식품류, 분말, 과립, 정제, 캡슐, 시럽제, 음료, 껌, 차, 비타민 복합제, 건강기능성식품류 등이 있다.Foods that can be added to the health functional food include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, tea, vitamin complexes, health functional foods, and the like.
상기 건강기능식품에 더 포함될 수 있는 첨가제로는, 천연 탄수 화물, 향미제, 영양제, 비타민, 광물(전해질), 풍미제(합성 풍미제, 천연 풍미제 등), 착색제, 충진제, 팩트산 및 그의 염, 일간산 및 그의 염, 유기산, 보호성 콜로이드 증점제, PH조절제, 안정화제, 방부제, 산화 방지제, 글리세린, 알콜, 탄산화제 및 과육으로 이루어진 군으로부터 선택된 1종 이상의 성분을 사용할 수 있다.Additives that may be further included in the health functional food include natural carbohydrates, flavoring agents, nutrients, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), coloring agents, fillers, lactic acid and its One or more components selected from the group consisting of salts, monoacids and salts thereof, organic acids, protective colloidal thickeners, PH regulators, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonation agents, and pulp may be used.
상기 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다.Examples of the natural carbohydrate include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
상기 향미제로서 천연 향미제(타우마틴, 스테비아추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.As the flavoring agent, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
또한, 상기 건강기능식품은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제, 팩트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, PH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition, the health functional food is various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and thickeners, facic acid and its salts, alginic acid and its salts, organic acids, protective properties colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
상기 담체, 부형제, 희석제 및 첨가제의 구체적인 예로는 이에 한정하는 것은 아니나, 락토스, 덱스트로즈, 슈크로즈, 솔비톨, 만니톨, 에리스리톨, 전분, 아카시아 고무, 인산칼슘, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 미세결정성 셀룰로즈, 폴리비닐키롤리돈, 셀룰로즈, 폴리비닐피로리돈, 메틸셀룰로즈, 물, 설탕시럽, 메틸 하이드록시 벤조에이트, 프로필하이드록시 벤조에이트, 활석, 스테아트산 마그네슘 및 미네랄 오일로 이루어진 그룹으로부터 선택된 1종 이상이 사용되는 것이 바람직하나, 이에 제한되는 것은 아니다.Specific examples of the carrier, excipient, diluent and additive include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate , microcrystalline cellulose, polyvinylkyrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil. At least one selected from the group is preferably used, but is not limited thereto.
본 발명의 다른 측면에 따르면, 호밀 추출밀, 아마씨 추출물, 밀배아 추출물, 및 보리지 추출물을 유효성분으로 포함하는 탈모 방지 및 발모 촉진용 화장료 조성물이 제공된다.According to another aspect of the present invention, there is provided a cosmetic composition for preventing hair loss and promoting hair growth comprising rye extract wheat, flaxseed extract, wheat germ extract, and borage extract as active ingredients.
상기 화장료 조성물은 아미노산 복합체(amino acid complex), 하이드롤라이즈드실크(hydrolyzed silk), 착향제, 세라마이드(Ceramide), 및 부형제를 더 포함할 수 있다.The cosmetic composition may further include an amino acid complex, hydrolyzed silk, a flavoring agent, ceramide, and an excipient.
상기 아미노산 복합체(amino acid complex)는 단백질의 기본 구성단위인 하나 이상의 아미노산이 혼합된 복합 조성물을 지칭하는 것으로, 혼합되는 아미노산의 종류 또는 혼합비는 특별히 제한되지 아니하며, 필요에 따라 달리 할 수 있다. 상기 아미노산 복합체는 피부에 보습력을 제공해주고, 모발에 윤기를 부여하므로 상기 조성물의 사용감을 증진시키고, 피부에 대한 자극을 최소화할 수 있다.The amino acid complex refers to a complex composition in which one or more amino acids, which are basic structural units of a protein, are mixed, and the type or mixing ratio of the amino acids to be mixed is not particularly limited, and may be changed as necessary. The amino acid complex provides moisture to the skin and gives shine to the hair, so it is possible to enhance the feeling of use of the composition and minimize irritation to the skin.
상기 하이드롤라이즈드실크(hydrolyzed silk) 견섬유를 산 또는 알칼리로 가수분해하여 얻은 펩타이드를 함유하는 물 또는 묽은 에탄올을 지칭하는 것으로 흔히 피부 또는 모발 컨디셔닝제의 용도로 사용될 수 있다. 상기 하이드롤라이즈드실크는 단백질의 구성 성분으로서 인체에 안전하며, 모발에 윤기 및 탄력을 부여하고 손상된 모발을 회복시킬 수 있다.The hydrolyzed silk (hydrolyzed silk) refers to water or dilute ethanol containing a peptide obtained by hydrolyzing the silk fibers with acid or alkali, and can often be used as a skin or hair conditioning agent. The hydrolyzed silk is safe to the human body as a component of protein, and it can give shine and elasticity to the hair and restore damaged hair.
상기 착향제는 식품이나 화장품 등에 넣어 향기를 내기 위해 첨가하는 물질을 지칭하는 것으로 상온에서 휘발성이 우수하며, 상기 조성물의 제품화를 위해 필요에 따라 첨가될 수 있다. 상기 착향제의 종류는 특별히 한정되지 않으며, 방향성 화학물질, 정유, 천연추출물, 증류물, 단리성분, 아로마, 수지성 레진 등이 사용될 수 있다. The flavoring agent refers to a substance added to food or cosmetics to give a fragrance, and has excellent volatility at room temperature, and may be added as necessary for commercialization of the composition. The type of the flavoring agent is not particularly limited, and aromatic chemicals, essential oils, natural extracts, distillates, isolated components, aromas, resinous resins, and the like may be used.
상기 세라마이드(Ceramide)는 피부 각질층을 구성하는 각질 세포간 지질 중 약 40% 이상을 차지하며 각질층의 구조 형성이나 기능을 나타내는 데 필수적인 성분으로서, 친수성기와 친유성기를 함께 가지므로 피부에 있는 수분의 증발을 억제할 수 있다. 상기 세라마이드는 모발에 수분막을 형성하여 수분 증발을 억제하고 손상을 방지하므로, 보습제의 원료로 첨가될 수 있다. The ceramide occupies about 40% or more of the lipid between the keratinocytes constituting the stratum corneum of the skin and is an essential component for the formation or function of the structure of the stratum corneum. can be suppressed. Since the ceramide forms a moisture film on the hair to inhibit moisture evaporation and prevent damage, it may be added as a raw material for a moisturizer.
상기 부형제(excipien)는 약제에 적당한 굳기나 형상을 부여하거나, 주제(主劑)의 양이 부족한 경우에 일정 용량, 중량을 주어 취급하기 쉬운 크기로 하기 위해 첨가하는 물질을 지칭하는 것으로, 그 종류는 특별히 한정되지 않으나, 락토오스, 녹말, 덱스트린, 글리세린, 셀룰로오스 등이 사용될 수 있다. The excipien refers to a substance added to give a drug an appropriate hardness or shape, or to give a certain amount and weight when the amount of the main agent is insufficient to make it a size that is easy to handle. is not particularly limited, but lactose, starch, dextrin, glycerin, cellulose, and the like may be used.
상기 화장료 조성물은 상기 첨가물들뿐만 아니라, 상기 조성물의 기능이나 용도를 고려하여 유화제, 보존제, 희석제, 색소 등 다양한 첨가제를 포함할 수 있다.The cosmetic composition may include various additives such as emulsifiers, preservatives, diluents, and pigments in consideration of the function or use of the composition as well as the additives.
상기 화장료 조성물은 일반적인 두피 및 모발용 외용제에 배합될 수 있는 기제 성분을 추가로 포함할 수 있고, 구체적으로 용해보조제, 계면활성제, 보습제, 점증제, pH 조정제, 방부제, 산화방지제, 금속이온봉쇄제, 살균제, 항염증제, 항미생물제, 용제, 착색제, 또는 착향제 등을 포함할 수 있다.The cosmetic composition may further include a base component that can be formulated in general external preparations for scalp and hair, and specifically, a solubilizing agent, a surfactant, a moisturizer, a thickener, a pH adjuster, a preservative, an antioxidant, a sequestering agent, fungicides, anti-inflammatory agents, antimicrobial agents, solvents, coloring agents, or flavoring agents, and the like.
상기 용해보조제는 이소프로필 미리스테이트, 폴리에틸렌 글리콜, 중쇄 지방산 트리글리세리드, 탄화수소, 글리콜류 등이 될 수 있다.The solubilizing agent may be isopropyl myristate, polyethylene glycol, medium-chain fatty acid triglycerides, hydrocarbons, glycols, and the like.
상기 계면활성제 중 음이온계 계면활성제는 암모늄 라우릴술포숙시네이트, 암모늄 라우릴 설페이트, 소디움 코코일이세시오네이트, 소디움 라우릴 이세시오네이트, 소디움 라우릴 설페이트, 트리에탄올아민 라우릴 설페이트, 소디움 라우릴 에테르 설페이트(에틸렌옥사이드 1∼3개) 등이 사용될 수 있다. 비이온성 계면활성제는 폴리옥시에틸렌알킬에테르, 폴리옥시에틸렌지방산 에스테르, 폴리옥시에틸렌, 경화 피마자유 유도체, 지방산 디에탄올아미드, 글리세릴스테아레이트 등이 사용될 수 있다. 양이온성 계면활성제는 3급 지방족 아민염, 알킬트리메칠암모늄클로라이드, 디알킬디메칠암모늄클로라이드 등이 사용될 수 있다. 양쪽성 계면활성제는 구체적으로 베타인, 아미드베타인형, 설포베타인형, 스테아르트리모늄클로라이드 등이 사용될 수 있다.Among the surfactants, anionic surfactants include ammonium lauryl sulfosuccinate, ammonium lauryl sulfate, sodium cocoyl sesionate, sodium lauryl isesionate, sodium lauryl sulfate, triethanolamine lauryl sulfate, and sodium lauryl sulfate. uryl ether sulfate (1 to 3 ethylene oxide) and the like can be used. Nonionic surfactants may include polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene, hydrogenated castor oil derivative, fatty acid diethanolamide, glyceryl stearate, and the like. Cationic surfactants may include tertiary aliphatic amine salts, alkyltrimethylammonium chloride, dialkyldimethylammonium chloride, and the like. Specifically, the amphoteric surfactant may be betaine, amide betaine, sulfobetaine, steartrimonium chloride, or the like.
상기 보습제는 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 디프로필렌글리콜, 소르비톨 등이 사용될 수 있다.The moisturizing agent may include glycerin, propylene glycol, 1,3-butylene glycol, dipropylene glycol, sorbitol, and the like.
상기 점증제는 메틸셀룰로스, 하이드록시에틸셀룰로스, 카라기난, 카르복시메틸셀룰로스, 하이드록시메틸셀룰로스 등의 수용성 고분자 화합물이 사용될 수 있다.As the thickener, a water-soluble high molecular compound such as methylcellulose, hydroxyethylcellulose, carrageenan, carboxymethylcellulose, and hydroxymethylcellulose may be used.
상기 pH 조정제는 구체적으로 구연산, 수산화나트륨, 트리에탄올아민, 구연산나트륨, 인산, 인산나트륨, 젖산 등이 사용될 수 있다.Specifically, the pH adjuster may include citric acid, sodium hydroxide, triethanolamine, sodium citrate, phosphoric acid, sodium phosphate, lactic acid, and the like.
상기 방부제는 벤조산, 파라옥시안식향산에스테르, 메칠클로로이소치아졸리논의 혼합물, 페녹시에탄올, 디엠디엠히단토인 등이 될 수 있고, 상기 산화방지제는 디부틸히드록시톨루엔, 아스코르빈산 등이 사용될 수 있다.The preservative may be benzoic acid, paraoxybenzoic acid ester, a mixture of methylchloroisothiazolinone, phenoxyethanol, DMDMhydantoin, etc., and the antioxidant may be dibutylhydroxytoluene, ascorbic acid, etc. .
상기 금속이온봉쇄제는 에칠렌디아민테트라초산디나트륨, 에칠렌디아민테트라초산테트라나트륨 등이 사용될 수 있고, 상기 살균제는 클로르헥시딘 글루코네이트, 4급 암모늄염, 피록톤올아민, 아연피리치온 현탁액, 요도프로피닐 부틸카바메이트, 살리실산 등이 사용될 수 있다.The sequestering agent may include disodium ethylenediaminetetraacetate, tetrasodium ethylenediaminetetraacetate, etc., and the disinfectant is chlorhexidine gluconate, quaternary ammonium salt, pyroctonolamine, zinc pyrithione suspension, iodopropynyl butyl. Carbamates, salicylic acid, and the like can be used.
상기 항염증제는 글리시리진산모노암모늄, 글리시리진산디칼륨, 스테아릴글리시리지네이트, 카모마일, 알파 비사보롤, 알란토인 등이 사용될 수 있고, 상기 항미생물제는 구체적으로 페녹시에탄올, 클로르헥시딘, 클로르헥시딘 글루코네이트, 피록톤올아민, 케토코나졸, 아르니카추출물, 요도프로피닐부틸카바메이트, 벤잘코늄클로라이드, 벤젠토늄클로라이드, 벤조산 및 그의 염, 벤질알코올, 라벤다, 로즈마리, 살리실산, 트리클로카르반, 아연피리치온 현탁액 등이 사용될 수 있다. The anti-inflammatory agent may include monoammonium glycyrrhizinate, dipotassium glycyrrhizinate, stearyl glycyrrhizinate, chamomile, alpha-bisabolol, allantoin, and the like, and the antimicrobial agent is specifically phenoxyethanol, chlorhexidine, chlorhexidine gluconate, and pyroctonol. Amine, ketoconazole, arnica extract, iodopropynyl butyl carbamate, benzalkonium chloride, benzenetonium chloride, benzoic acid and its salts, benzyl alcohol, lavender, rosemary, salicylic acid, triclocarban, zinc pyrithione suspension, etc. can be used.
상기 용제는 에탄올, 정제수, 트윈 20, 사이클로메치콘, 미네랄오일, 디메치콘 등이 사용될 수 있고, 상기 착색제 및 착향제는 두피 및 모발용 제제에 사용되는 통상의 기제들을 사용할 수 있다.As the solvent, ethanol, purified water, Tween 20, cyclomethicone, mineral oil, dimethicone, etc. may be used, and the colorant and flavoring agent may be conventional bases used in scalp and hair preparations.
한편, 상기 조성물은 유액, 크림, 페이스트, 겔, 화장수, 팩, 로션, 파우더, 스프레이, 비누 등의 모발처리용 조성물로서 제형화될 수 있고, 구체적으로 헤어토너, 헤어로션, 헤어크림, 헤어스프레이, 헤어무스, 헤어젤, 헤어비누, 헤어샴푸, 헤어린스, 헤어팩, 및 헤어트리트먼트로로 이루어진 군에서 선택된 하나 이상으로 제형화될 수 있고, 구체적으로 액상형 헤어샴푸로 제형화될 수 있다.On the other hand, the composition may be formulated as a composition for hair treatment such as emulsion, cream, paste, gel, lotion, pack, lotion, powder, spray, soap, etc., specifically, hair toner, hair lotion, hair cream, hair spray. , hair mousse, hair gel, hair soap, hair shampoo, hair conditioner, hair pack, and hair treatment may be formulated with one or more selected from the group consisting of, and specifically formulated as a liquid hair shampoo.
상기 제형에 있어서, 상기한 필수성분 이외에 다른 성분들은 기타 외용제의 용도 또는 사용목적에 따라 당업자가 적절하게 선정하여 배합할 수 있다.In the formulation, other components in addition to the above-mentioned essential components may be appropriately selected and formulated by those skilled in the art according to the use or purpose of use of other external preparations.
예컨대, 상기 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 사용될 수 있다.For example, when the formulation of the composition is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide as a carrier component. can be used
상기 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히, 추가적으로 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진체를 더 포함할 수 있다.When the formulation of the composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, additionally chlorofluorohydrocarbon, propane, butane or It may further contain a propellant such as dimethyl ether.
상기 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 사용될 수 있고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 사용될 수 있다. When the formulation of the composition is a solution or emulsion, a solvent, solvating agent or emulsifying agent may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan may be used.
상기 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 사용될 수 있다.When the formulation of the composition is a suspension, as a carrier component, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.
이하 실시예를 통해, 본 발명을 더욱 상술하나 하기 실시예에 의해 본 발명이 제한되지 아니함은 자명하다.Through the following examples, the present invention will be described in more detail, but it is obvious that the present invention is not limited by the following examples.
제조예 : 천연 추출물의 제조Preparation Example: Preparation of natural extract
호밀, 소나무 껍질, 및 모링가를 각각 수세한 후 상온에서 완전히 건조시키고 분쇄물을 100g씩 수득하였다.Rye, pine bark, and moringa were each washed with water, dried completely at room temperature, and 100 g of a pulverized product was obtained.
각각의 분쇄물 100g에 대해 20배 부피의 에탄올을 용매로 하여 50℃의 온도에서 24시간 동안 침적 추출하였다. For 100 g of each pulverized product, immersion extraction was performed at a temperature of 50° C. for 24 hours using 20 times the volume of ethanol as a solvent.
아마씨, 보리지, 밀배아, 톱야자 열매는 각각 건조시킨 후 물리적으로 압착하여 오일 형태로 추출물을 수득하였다.Flaxseed, barley, wheat germ, and saw palmetto fruit were each dried and then physically compressed to obtain an extract in the form of an oil.
상기 추출물은 250메쉬 및 3㎛ 필터 에 의해 여과되었으며, 잔여 원료에 대해 동일한 방법으로 3회 반복 추출 하고, 50℃에서 감압 농축 후 동결 건조하여 고형분을 수득하였다. The extract was filtered through a 250 mesh and 3 μm filter, and the remaining raw materials were extracted three times in the same manner, concentrated under reduced pressure at 50° C., and then freeze-dried to obtain a solid.
실시예 및 비교예Examples and Comparative Examples
수득한 추출물의 안정성 및 기능성을 검증하고자 하기 표 1 및 2와 같이 시료를 혼합하여 실시예 및 비교예를 설정하였다.Examples and Comparative Examples were set by mixing samples as shown in Tables 1 and 2 below to verify the stability and functionality of the obtained extract.
실험예 1 : 피부 안전성 평가Experimental Example 1: Skin safety evaluation
실시예 및 비교예의 시료에 대한 피부 안전성을 검증하기 위해, 섬유아세포(HDF)에 대한 MTT assay 실험을 수행하였다.In order to verify the skin safety of the samples of Examples and Comparative Examples, an MTT assay experiment for fibroblasts (HDF) was performed.
실시예 및 비교예의 시료를 정제수에 25, 50, 100, 200, 400 μg/mL의 농도별로 각각 현탁한 후, 세포 생존율을 측정하였다.After each of the samples of Examples and Comparative Examples were suspended in purified water at concentrations of 25, 50, 100, 200, and 400 μg/mL, cell viability was measured.
세포 독성은 MTT{3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide} 시약을 이용하여 세포 생존율을 측정하는 모스만(Mosmann)의 방법을 변형하여 수행하였다.Cytotoxicity was performed by modifying Mosmann's method for measuring cell viability using MTT {3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide} reagent.
섬유아세포(HDF)를 각각 96-웰 플레이트에 1×104 cells/well의 농도로 분주하여 37℃, 5% CO2에서 48시간 동안 배양하였다.Fibroblasts (HDF) were each dispensed in a 96-well plate at a concentration of 1×10 4 cells/well and cultured at 37° C., 5% CO 2 for 48 hours.
배양 배지를 제거하고 시료를 농도별로 처리한 배지에 48시간 동안 배양한 후 배지를 제거하고 PBS(Phosphate buffered saline)로 반복 세척하였다.After removing the culture medium and culturing the sample in a medium treated for each concentration for 48 hours, the medium was removed and washed repeatedly with PBS (Phosphate buffered saline).
MTT를 5mg/mL로 PBS에 녹여 50 μL 첨가하고 37℃, 5%의 CO2에서 48시간 동안 배양하였다. DMSO(Dimethyl sulfoxide)를 한 웰(well) 당 100L 넣고, 10분 동안 교반한 후 540nm에서 흡광도를 측정하였다.MTT was dissolved in PBS at 5 mg/mL, 50 μL was added, and incubated at 37° C., 5% CO 2 for 48 hours. 100 L of DMSO (dimethyl sulfoxide) was added per well, and the absorbance was measured at 540 nm after stirring for 10 minutes.
측정 결과, 각 시료의 모든 농도에서 세포 독성은 확인되지 않았다. 기 결과는 상기 시료가 인체에 무해할 뿐만 아니라 인체 안전성이 우수함을 시사한다.As a result of the measurement, cytotoxicity was not confirmed at all concentrations of each sample. These results suggest that the sample is not only harmless to the human body, but also has excellent human safety.
실험예 2 : 모유두세포 증식 촉진 효과 평가Experimental Example 2: Evaluation of the effect of promoting dermal papilla cell proliferation
온도 민감 T 항원을 인코딩한 폴리오마바이러스 라지 T 유전자(polyomavirus large T gene)를 트랜스펙션하여 제조한 PVG 쥐수염 모유두세포(Rat Vibrissa dermal papillae cell)를 이용하여 실시예 및 비교예 시료의 모유두세포 증식 촉진 효과를 평가하였다.The dermal papilla cells of Examples and Comparative Examples using PVG Rat Vibrissa dermal papillae cells prepared by transfection of a polyomavirus large T gene encoding a temperature-sensitive T antigen The proliferation promoting effect was evaluated.
상기 모유두세포를 6-웰 플레이트에 한 웰 당 약 104 세포/웰의 농도로 배양하였다.The dermal papilla cells were cultured in a 6-well plate at a concentration of about 10 4 cells/well per well.
실시예 및 비교예의 시료를 DMSO(Dimethyl sulfoxide) 또는 에탄올에 각각 용해시킨 후, 5% FBS 혈청 농도의 DMEM 배지로 순차적 희석(serial dilution)하여 최종 농도를 10ppm으로 조절하였다.After each of the samples of Examples and Comparative Examples were dissolved in DMSO (dimethyl sulfoxide) or ethanol, the final concentration was adjusted to 10 ppm by serial dilution with DMEM medium with 5% FBS serum concentration.
실시예 및 비교예의 시료가 첨가된 배지 200μL를 각각 웰 당 첨가한 후, 37℃ 5% CO2 배양기에서 약 3일간 배양하였으며, MTT 용액을 각 웰 당 50μL씩 첨가한 후, 동일한 배양기에서 4시간 동안 더 배양하였다. After adding 200 μL of the medium to which the samples of Examples and Comparative Examples were added per well, incubated for about 3 days at 37° C. 5% CO 2 Incubator, after adding 50 μL of MTT solution to each well, 4 hours in the same incubator incubated for more.
MTT 시약이 세포 내 미토콘드리아에 흡수된 후 상등액을 제거하고, DMSO를 150μL 첨가하였으며, 10분간 교반하여 균일하게 프로마잔(formazan) 염료(dye)를 용해시켰다.After the MTT reagent was absorbed into the mitochondria in the cell, the supernatant was removed, 150 μL of DMSO was added, and stirred for 10 minutes to uniformly dissolve the formazan dye (dye).
515nm 파장에서 ELISA 리더를 이용하여 O.D. 값을 측정하였으며, 미리 만들어둔 표준 곡선에 맞추어 세포 수를 측정하였다. O.D. using an ELISA reader at 515nm wavelength. The value was measured, and the number of cells was measured according to a standard curve prepared in advance.
측정한 세포 수를 기초로 실시예 및 비교예의 모유두 세포 증식 촉진능(%)을 계산하였다. 평가 결과는 하기 표 3과 같다.Based on the measured cell number, the dermal papilla cell proliferation promoting ability (%) of Examples and Comparative Examples was calculated. The evaluation results are shown in Table 3 below.
표 3을 참조하면, 실시예의 혼합 시료는 비교예의 시료와 비교하여 현저하게 우수한 모두유 세포 증식 촉진 효과를 나타내었으며, 시료의 복합 적용에 따른 시너지 효과가 규명되었다.특히, 실시예 2 내지 6의 시료는 실시예1과 비교하여 세포 증식을 더욱 촉진하였으므로, 탈모 방지 및 육모 촉진 효과가 매우 우수한 것으로 평가할 수 있다. Referring to Table 3, the mixed samples of Examples exhibited remarkably superior effects on promoting proliferation of flow cells compared to the samples of Comparative Examples, and a synergistic effect was identified according to the complex application of the samples. In particular, Examples 2 to 6 Since the sample further promoted cell proliferation compared to Example 1, it can be evaluated that the hair loss prevention and hair growth promoting effect are very excellent.
실험예 3 : 모세혈관 확장효과 평가Experimental Example 3: Evaluation of capillary dilation effect
실시예 및 비교예 시료의 모세혈관 확장효과를 평가하고자, 섬유아세포(fibroblast)의 증식 정도를 측정하였다.In order to evaluate the capillary dilatation effect of the samples of Examples and Comparative Examples, the degree of proliferation of fibroblasts was measured.
칼륨통로는 활성화되어 미토제네시스(mitogenesis)를 촉진하고, 혈관 평활근(vascular smooth muscle)을 이완시켜 혈관의 확장을 유도하는 반면, 차단에 의해 NIH3T3 섬유아세포(fibroblast)의 증식을 촉진하므로 섬유아세포의 증식 정도를 평가하여 칼륨통로의 개방 여부를 확인할 수 있다.Potassium channel is activated to promote mitogenesis, relax vascular smooth muscle to induce vascular expansion, while blocking promotes proliferation of NIH3T3 fibroblasts, so fibroblast proliferation By evaluating the degree, it is possible to check whether the potassium channel is open.
시료의 모세혈관 확장능을 평가하기 위해, NIH3T3 섬유아세포를 24-웰 배양 플레이트에 104 세포/웰의 농도로 시드(seed)하고, 10% FCS(fetal calf serum) 및 2mM L-글루타민을 포함하며 항생제를 포함하지 않는 DMEM 배지에 24시간 동안 배양하였다. To evaluate the capillary dilatation capacity of the sample, NIH3T3 fibroblasts were seeded in a 24-well culture plate at a concentration of 10 4 cells/well, and 10% fetal calf serum (FCS) and 2mM L-glutamine were included. and cultured in DMEM medium without antibiotics for 24 hours.
한편, 상기 배양된 배지를 실험예 1과 동일한 방법으로 제조된 실시예 및 비교예의 추출물이 첨가된 각 배지로 교체하고 72시간 동안 더 배양하였다. On the other hand, the cultured medium was replaced with each medium to which the extracts of Examples and Comparative Examples prepared in the same manner as in Experimental Example 1 were added, and further cultured for 72 hours.
이때, 배지를 제거한 후 PBS(Ca2+/Mg2+ 없음)로 세척하였으며, 0.5ml TE(trypsin-ethylenediamine tetraacetic acid)로 처리한 후 배양하였다.At this time, after removing the medium, it was washed with PBS (No Ca 2+ /Mg 2+ ), treated with 0.5ml TE (trypsin-ethylenediamine tetraacetic acid), and then cultured.
10%(v/v) FCS가 포함된 DMEM를 첨가하고 세포를 분리한 후 EP 튜브에 넣어 5500rpm에서 원심 분리하였다.DMEM containing 10% (v/v) FCS was added and the cells were separated, placed in an EP tube, and centrifuged at 5500 rpm.
상등액을 제거한 후 남은 세포액을 100μL의 PBS에 현탁한 후 혈구 계산기(hemocytometer)를 통해 세포수를 카운팅하였다.After removing the supernatant, the remaining cell solution was suspended in 100 μL of PBS, and the number of cells was counted using a hemocytometer.
상기 결과에 따라 측정된 실시예 및 비교예의 모세혈관 확장효과는 하기 표 4와 같다.The capillary dilatation effects of Examples and Comparative Examples measured according to the above results are shown in Table 4 below.
표 4를 참조하면, 실시예의 혼합 시료는 비교예의 시료와 비교하여 모세혈관 확장효과가 현저하게 우수하였다. 특히, 실시예 2 내지 6의 시료는 실시예1과 비교하여 모세혈관 확장효과가 더욱 우수하였으므로, 두피 모세혈관의 혈액 순환을 개선하여 모발 건강을 증진시키고 탈모의 진행을 억제할 수 있는 것으로 평가된다.Referring to Table 4, the mixed sample of Example was significantly superior to the capillary dilatation effect compared to the sample of Comparative Example. In particular, since the samples of Examples 2 to 6 had better capillary dilatation effect compared to Example 1, it is evaluated that it is possible to improve the blood circulation of the scalp capillaries to promote hair health and inhibit the progress of hair loss. .
실험예 4 : 발모 촉진 활성 평가Experimental Example 4: Evaluation of hair growth promoting activity
모발이 휴지기에 들어선 생후 약 50일 된 생쥐(C57BL/6)의 모발을 제거한 후 실시예 및 비교예의 모발 성장 촉진 효과를 평가하였다.After hair removal of about 50-day-old mice (C57BL/6) in which the hair entered the telogen phase, the hair growth promoting effect of Examples and Comparative Examples was evaluated.
본 실험에서 몸무게, 크기 등 특성이 유사한 생쥐를 5마리씩 18군으로 나눈 후 개별적으로 사육하여 모발의 성장 정도를 측정하였다.In this experiment, mice with similar characteristics such as weight and size were divided into 18 groups of 5 each, and then individually bred to measure the degree of hair growth.
실시예 및 비교예의 시료를 1.0 중량% 포함하는 시리얼 사료를 섭취하도록 한 후 30일간 사육하고 제모 부위에서 성장한 모발을 분리하여 중량을 측정하였다. After ingesting a cereal feed containing 1.0% by weight of the samples of Examples and Comparative Examples, they were bred for 30 days, and the hairs grown in the hair removal area were separated and the weight was measured.
실시예 및 비교예의 시료를 포함하지 않는 시리얼 사료를 섭취한 생쥐를 대조군으로 설정하여 추출물에 의한 모발 성장 촉진 효과를 더욱 명확하게 평가하였다. 측정 결과는 하기 표 5와 같다.The hair growth promoting effect of the extract was more clearly evaluated by setting the mice fed the cereal feed not containing the samples of Examples and Comparative Examples as a control group. The measurement results are shown in Table 5 below.
표 5를 참조하면, 실시예의 혼합 시료는 비교예의 시료와 비교하여 모발 성장 촉진 효과가 현저하게 우수하였다. Referring to Table 5, the mixed sample of Example was significantly superior to the hair growth promoting effect compared to the sample of Comparative Example.
특히, 실시예 2 내지 6의 시료는 실시예1과 비교하여 모발 성진 촉진 효과가 더욱 우수하였으므로 모발 건강을 증진 시키고 탈모를 억제할 수 있을 것으로 평가된다.In particular, the samples of Examples 2 to 6 were evaluated to be able to improve hair health and inhibit hair loss because the hair growth promoting effect was more excellent compared to Example 1.
실험예 5 : 자유라디칼 소거 활성 평가Experimental Example 5: Evaluation of free radical scavenging activity
상기 실시예 및 비교예의 추출물을 정제수에 현탁(농도 10%)하여 자유라디칼 소거 활성(free radical scavenging acticity)을 평가하였다.The extracts of Examples and Comparative Examples were suspended in purified water (concentration of 10%) to evaluate free radical scavenging activity.
DPPH 측정법은 억제제(inhibitor)가 안정한 라디칼 DPPH(2,2-Diphenyl-1-picrylhydrazyl radical)를 소거하여 탈색되는 정도를 540 nm에서 흡광도를 측정하는 방법이다. The DPPH measurement method is a method of measuring the absorbance at 540 nm to determine the extent to which an inhibitor is decolorized by scavenging a stable radical DPPH (2,2-diphenyl-1-picrylhydrazyl radical).
대조군으로서 디부틸히드록시톨루엔(BHT, Dibutyl hydroxy toluene)을 이용하여 자유라디칼 소거 활성을 명확히 비교하였다. Free radical scavenging activity was clearly compared using dibutyl hydroxy toluene (BHT) as a control.
디부틸히드록시톨루엔은 무색의 결정, 또는 백색의 결정성 분말로 항산화 효과가 우수하여 식용유지, 유지성 식품의 산화방지제로 널리 사용되고 있다. Dibutylhydroxytoluene is a colorless crystal or white crystalline powder that has excellent antioxidant effect and is widely used as an antioxidant in edible oils and fats.
실험의 정확도를 위하여 동일한 실험을 3회 반복하였으며, 결과는 하기 표 6과 같다. The same experiment was repeated 3 times for the accuracy of the experiment, and the results are shown in Table 6 below.
표 6을 참조하면, 실시예의 시료는 농도가 증가함에 따라 자유라디칼 소거활성이 증가하였으며, 비교예의 시료와 비교하여 자유라디칼 소거활성이 현저히 우수하였다.자유라디칼 소거활성이 높을수록 항산화 효과가 뛰어난 것으로 평가할 수 있으며, Referring to Table 6, the free radical scavenging activity of the sample of Example increased as the concentration increased, and the free radical scavenging activity was significantly superior to that of the sample of Comparative Example. The higher the free radical scavenging activity, the better the antioxidant effect. can be evaluated,
특히, 실시예 2 내지 6의 시료는 실시예1과 비교하여 항산화 효과가 더욱 우수하였다.In particular, the samples of Examples 2 to 6 were more excellent in antioxidant effect than in Example 1.
실험예 6 : 항염 활성 평가Experimental Example 6: Evaluation of anti-inflammatory activity
Lipopolysaccharide(LPS)로 자극을 유도한 쥐 대식세포주 RAW 264.7 cell에서 EAME의 NO 생성 억제능을 분석하여 실시예 및 비교예의 항염 활성을 평가하였다.The anti-inflammatory activity of Examples and Comparative Examples was evaluated by analyzing the NO production inhibitory ability of EAME in RAW 264.7 cell, a mouse macrophage cell line induced by lipopolysaccharide (LPS) stimulation.
실험을 위해 Murine macrophage cell line 인 Raw 264.7 세포를 한국 세포주 은행으로부터 분양 받아 100units/mL penicillin-streptomycin과 10% fetal bovine serum(FBS)이 함유된 DMEM 배지를 사용하여 37℃ 5% CO2 incubator에서 배양하였으며, 2 내지 3일에 한번씩 계대 배양을 실시하였다. For the experiment, Raw 264.7 cells, a murine macrophage cell line, were distributed from the Korean cell line bank and cultured in a 5% CO 2 incubator at 37°C using DMEM medium containing 100 units/mL penicillin-streptomycin and 10% fetal bovine serum (FBS). and subculture was performed once every 2-3 days.
Raw 264.7 세포(3 X 105 cells/mL)를 18시간 전 배양 후, 실시예 및 비교예의 시료(농도 10%)와 LPS(1 μg/mL)를 동시 처리하여 24시간동안 배양하였다. Raw 264.7 cells (3 X 10 5 cells/mL) were cultured 18 hours before, and the samples of Examples and Comparative Examples (concentration 10%) and LPS (1 μg/mL) were simultaneously treated and cultured for 24 hours.
생성된 NO는 Griess reagent을 이용하여 세포 배양액 중 존재하는 NO2 -의 형태로 측정하였다. The generated NO was measured in the form of NO 2 − present in the cell culture medium using Griess reagent.
음성 대조군은 LPS를 처리하지 않았으며, 양성 대조군은 LPS만을 처리하여 생성된 NO량을 측정하였다. The negative control group was not treated with LPS, and the positive control group was treated with only LPS to measure the amount of NO generated.
세포 배양 상층액 100μL 및 Griess 시약(1%(w/v) sulfanilamide, 0.1%(w/v) naphtylehtylenediamine in 2.5%(v/v) phosphoric acid)을 동량 혼합하여 10분간 실온 암실에서 반응시킨 후 ELISA reader를 이용하여 흡광도(540nm)를 측정하였다. 100 μL of cell culture supernatant and Griess reagent (1% (w/v) sulfanilamide, 0.1% (w/v) naphtylehtylenediamine in 2.5% (v/v) phosphoric acid) were mixed in equal amounts and reacted in the dark at room temperature for 10 minutes, followed by ELISA Absorbance (540 nm) was measured using a reader.
표준농도 곡선은 sodium nitrite(NaNO2)를 serial dilution하여 얻었다(10-100μM).The standard concentration curve was obtained by serial dilution of sodium nitrite (NaNO 2 ) (10-100 μM).
표 7을 참조하면, 실시예의 혼합 시료는 비교예의 시료와 비교하여 더 높은 NO(Nitric oxide) 생성 억제 활성을 나타냈으며, 항산화 및 항염증 활성이 현저히 우수하였다.Referring to Table 7, the mixed sample of Example exhibited a higher NO (nitric oxide) production inhibitory activity compared to the sample of Comparative Example, and was remarkably excellent in antioxidant and anti-inflammatory activity.
실험예 7 : 항균 활성 평가Experimental Example 7: Evaluation of antibacterial activity
실시예 및 비교예 시료의 항균 활성을 평가하였다. 공시균으로서 피티로스포룸 오발(Pityrosporum ovale ATCC 12087)을 사용하였으며 양성 대조군으로서 화학합성 항균제인 트리클로산을 사용하였다.The antibacterial activity of the samples of Examples and Comparative Examples was evaluated. Pityrosporum ovale ATCC 12087 was used as a test bacteria, and triclosan, a chemically synthesized antibacterial agent, was used as a positive control.
프로피오니박테리움 아크네스균은 5% sheep blood가 포함된 tryptic soy agar 배지에 striking하여 2 내지 3일 정도 배양 하여 미리 준비해 둔 McFaland nephleometer standards 0.5(1% Barum chloride(0.05 ml) + 1% Sulfuric acid(9.95 ml))의 탁도와 동일하게 하면 균의 농도는 1x108 cells/mL이었다.Propionibacterium acnes was struck on tryptic soy agar medium containing 5% sheep blood and cultured for 2 to 3 days in advance, prepared by McFaland nephleometer standards 0.5 (1% Barum chloride (0.05 ml) + 1% Sulfuric acid). (9.95 ml)), the concentration of bacteria was 1x10 8 cells/mL.
액체 BHI배지 2ml에 각 시료를 0에서 2000ppm까지 100ppm 간격으로 희석한 후, 1x108 cells/mL의 균액 20μL를 접종하여 48시간 동안 배양시켰다.After diluting each sample in 2ml of liquid BHI medium at intervals of 100ppm from 0 to 2000ppm, 20μL of 1x10 8 cells/mL bacterial solution was inoculated and cultured for 48 hours.
혼탁도를 기준으로 성장이 저해된 최소농도를 최저 성장저해농도(MIC)로 정의하였으며, 결과는 하기 표 8과 같다.Based on the turbidity, the minimum concentration inhibiting growth was defined as the minimum growth inhibitory concentration (MIC), and the results are shown in Table 8 below.
표 8을 참조하면 실시예의 혼합 시료는 양성 대조군인 트리클로산과 비교하여 항균 효과가 다소 미약하였으나, 비교예의 시료와 비교하여 항균 효과가 현저히 우수하였다. Referring to Table 8, the mixed sample of Example had a rather weak antibacterial effect compared to triclosan, a positive control, but had significantly superior antibacterial effect compared to the sample of Comparative Example.
특히, 실시예 2 내지 6의 시료는 실시예1과 비교하여 비듬균에 대한 항균 효과가 더욱 우수하였다.In particular, the samples of Examples 2 to 6 were more excellent in the antibacterial effect against dandruff compared to Example 1.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.The description of the present invention described above is for illustration, and those of ordinary skill in the art to which the present invention pertains can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. For example, each component described as a single type may be implemented in a dispersed form, and likewise components described as distributed may also be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the following claims, and all changes or modifications derived from the meaning and scope of the claims and their equivalents should be construed as being included in the scope of the present invention.
Claims (9)
소나무 껍질 추출물 또는 톱야자 추출물을 더 포함하는 약학 조성물.According to claim 1,
A pharmaceutical composition further comprising a pine bark extract or saw palmetto extract.
모링가 추출물을 더 포함하는 약학 조성물.3. The method of claim 2,
A pharmaceutical composition further comprising a Moringa extract.
비오틴을 더 포함하는 약학 조성물.4. The method of claim 3,
A pharmaceutical composition further comprising biotin.
항염, 항균 활성 및 세포 증식능을 더 포함하는 약학 조성물.5. The method according to any one of claims 1 to 4,
Pharmaceutical composition further comprising anti-inflammatory, antibacterial activity and cell proliferation.
소나무 껍질 추출물 또는 톱야자 추출물을 더 포함하는 식품 조성물.7. The method of claim 6,
A food composition further comprising a pine bark extract or saw palmetto extract.
헤어토너, 헤어로션, 헤어크림, 헤어스프레이, 헤어무스, 헤어젤, 헤어비누, 헤어샴푸, 헤어린스, 헤어팩, 및 헤어트리트먼트로로 이루어진 군에서 선택된 하나 이상으로 제형화된 화장료 조성물.
9. The method of claim 8,
A cosmetic composition formulated with one or more selected from the group consisting of hair toner, hair lotion, hair cream, hair spray, hair mousse, hair gel, hair soap, hair shampoo, hair rinse, hair pack, and hair treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200183916A KR102429214B1 (en) | 2020-12-24 | 2020-12-24 | A composition for stimulating growth of hairs contaning natural complex extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200183916A KR102429214B1 (en) | 2020-12-24 | 2020-12-24 | A composition for stimulating growth of hairs contaning natural complex extracts |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220092745A true KR20220092745A (en) | 2022-07-04 |
KR102429214B1 KR102429214B1 (en) | 2022-08-05 |
Family
ID=82399116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200183916A KR102429214B1 (en) | 2020-12-24 | 2020-12-24 | A composition for stimulating growth of hairs contaning natural complex extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102429214B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120136583A (en) * | 2011-06-09 | 2012-12-20 | (주)아모레퍼시픽 | Composition for prevention of losing hair or promotion of growing hair |
-
2020
- 2020-12-24 KR KR1020200183916A patent/KR102429214B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120136583A (en) * | 2011-06-09 | 2012-12-20 | (주)아모레퍼시픽 | Composition for prevention of losing hair or promotion of growing hair |
Also Published As
Publication number | Publication date |
---|---|
KR102429214B1 (en) | 2022-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20210087405A (en) | Compositions Containing Plant Extracts | |
KR20190079202A (en) | Fermentation method of lactic acid bacteria using citrus fruit and its use | |
KR101059471B1 (en) | Cosmetic composition for skin aging | |
KR102358623B1 (en) | Food composition for improving skin condition comprising collagen peptide | |
KR20200091361A (en) | Compositions for promoting hair growth or preventing hair loss comprising a complex extract of cucumber, eggplant and snail | |
KR101907921B1 (en) | Composition for preventing or ameliorating skin wrinkle comprising Schisandra chinensis extract as effective component | |
JP6055667B2 (en) | Collagen production promoter | |
KR101598083B1 (en) | An antifungal composition comprising an natural fermentation material | |
KR20220112888A (en) | Functional collagen composition using collagen amino acid derived from Aurea Helianthus | |
JP2003055244A (en) | Agent promoting hyaluronic acid production, cosmetics, food and beverage including the hyaluronic acid production-promoting agent | |
JP2023118853A (en) | Anti-aging composition, anti-aging skin cosmetics and anti-aging food and drink | |
CN113631227A (en) | Antiaging agent, antioxidant, antiinflammatory agent, whitening agent, and cosmetic | |
KR102458480B1 (en) | A composition for stimulating growth of hairs contaning rhynchosia nulubilis complex extracts | |
KR20210048021A (en) | Antibacterial compositions comprising the citrus aurantium sinensis peel extract, the magnolia officinalis bark extract and polylysine | |
KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract | |
KR102429214B1 (en) | A composition for stimulating growth of hairs contaning natural complex extracts | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR102343245B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Chrysanthemum indicum L. oil extract as effective component | |
KR20220163542A (en) | Composition for anti-oxidation, anti-inflammation, and anti-pollution containing an extraction of Backhousia citriodora and Sparassis crispa | |
KR20220099176A (en) | A composition with anti-inflammation activity and skin elasticity improvement efficacy comprising mixed ferment extracts of natural products | |
JP2011126824A (en) | Fat accumulation inhibitor | |
KR101695372B1 (en) | Composition for improving wrinkle and elasticity containing ribes nigrum extracts | |
KR20170065956A (en) | A composition comprising bark of Cinnamomum loureirii extract having anti-oxidative or anti-inflammatory activity | |
TWI857919B (en) | Anti-inflammatory agents and cosmetics | |
KR20180104960A (en) | Composition comprising extracts of banana, cherry, and walnut for anti-skin aging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |